Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00196378 · ClinicalTrials.gov registry record · Phase 3

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

A Phase 3 study, sponsored by Duramed Research.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target

NCT00196378: Completed Phase 3 study, sponsored by Duramed Research.

NCT00196378 is a Phase 3 study that has completed, run by Duramed Research. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00196378, a Phase 3 study, has completed, sponsored by Duramed Research.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target

Study Summary

This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.

Interventions

  • OTHER Placebo
  • DRUG Synthetic Conjugated estrogens, B

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2004-11
Est. Completion 2006-02
Phase Phase 3
Duramed Research

23 total trials

What the finished NCT00196378 record still lists

NCT00196378 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00196378 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00196378 about?

NCT00196378 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy". This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.

What is the current status of trial NCT00196378?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-11. Estimated completion is 2006-02.

What interventions are being tested in trial NCT00196378?

The interventions under investigation include: Placebo (OTHER), Synthetic Conjugated estrogens, B (DRUG).

Who is sponsoring clinical trial NCT00196378?

This trial is sponsored by Duramed Research, which has 23 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00196378's enrollment target sits among peer trials

300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00196378, the US trial registry maintained by the National Library of Medicine. NCT00196378 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.